选择性糖皮质激素受体调节剂 relacorilant 与纳布-紫杉醇联合治疗复发性铂类耐药卵巢癌患者的随机、开放标签 II 期研究的最终总生存期数据

IF 4.5 2区 医学 Q1 OBSTETRICS & GYNECOLOGY
Nicoletta Colombo , Toon Van Gorp , Ursula Matulonis , Ana Oaknin , Rachel Grisham , Diane Provencher , Gini Fleming , Alexander Olawaiye , Hristina Pashova , Iulia Cristina Tudor , Lyndah Dreiling , Domenica Lorusso
{"title":"选择性糖皮质激素受体调节剂 relacorilant 与纳布-紫杉醇联合治疗复发性铂类耐药卵巢癌患者的随机、开放标签 II 期研究的最终总生存期数据","authors":"Nicoletta Colombo , Toon Van Gorp , Ursula Matulonis , Ana Oaknin , Rachel Grisham , Diane Provencher , Gini Fleming , Alexander Olawaiye , Hristina Pashova , Iulia Cristina Tudor , Lyndah Dreiling , Domenica Lorusso","doi":"10.1016/j.ygyno.2024.07.109","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12853,"journal":{"name":"Gynecologic oncology","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer\",\"authors\":\"Nicoletta Colombo , Toon Van Gorp , Ursula Matulonis , Ana Oaknin , Rachel Grisham , Diane Provencher , Gini Fleming , Alexander Olawaiye , Hristina Pashova , Iulia Cristina Tudor , Lyndah Dreiling , Domenica Lorusso\",\"doi\":\"10.1016/j.ygyno.2024.07.109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12853,\"journal\":{\"name\":\"Gynecologic oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gynecologic oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0090825824004645\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0090825824004645","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
Final overall survival data from a randomized, open-label, phase II study of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel among patients with recurrent platinum-resistant ovarian cancer
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Gynecologic oncology
Gynecologic oncology 医学-妇产科学
CiteScore
8.60
自引率
6.40%
发文量
1062
审稿时长
37 days
期刊介绍: Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信